Ascendis Pharma reports Q3 results on September 4 with the Street firmly bullish but modestly dialling back expectations — while short interest has quietly built to its highest level in six weeks.
The analyst picture has shifted slightly since the previous note. Oppenheimer's Leland Gershell moved in the opposite direction on Wednesday, raising his target to $312 from $304 while reiterating Outperform. That follows Morgan Stanley trimming to $273 from $275 on Tuesday — a token cut, but notable given the firm's bellwether status. The broader pattern remains intact: targets have been nudging lower across the board since Monday, with multiple Buy-rated firms trimming by $2-4 apiece, yet no one is changing their rating. The consensus is firmly bullish, with the mean target of $271 sitting only about 4% above the current price of $260. Wedbush's $327 and HC Wainwright's $344 anchors are at the optimistic end; Morgan Stanley's $273 is closer to where the stock trades. The bull thesis centres on Ascendis's rare-disease pipeline and a long-run €10 billion revenue ambition, while bears flag competition from VOXZOGO in the growth hormone market, regulatory uncertainty, and heavy reliance on the US reimbursement environment. One bright spot: the EPS surprise factor ranks in the 95th percentile — the company has beaten estimates consistently, which gives the September 4 print added significance.
Short interest has been building steadily, though it remains a secondary rather than primary story. Estimated short shares have risen roughly 28% over the past month — from around 2.94 million to 3.78 million — and climbed another 6.7% in the past week alone. That pace is worth flagging, even if the absolute level is modest relative to the float. The lending market remains completely untroubled: availability is extraordinarily loose at over 2,190%, meaning there are more than 18 million shares available to borrow against roughly 3.8 million already shorted. Borrowing costs have ticked up 23% over the week to 0.44%, but that still represents a near-frictionless borrow. The ORTEX short score has drifted up to 45.5 from 43 two weeks ago — moving in the right direction for bears but far from an extreme reading. The picture here is one of measured, incremental short-side interest building into an event, not a conviction-driven pile-on.
Options positioning has eased slightly but remains more defensive than the summer norm. The put/call ratio dropped back to 0.47 on Tuesday after touching 0.52 on Monday — still above the 20-day average of 0.38, and representing about 1.2 standard deviations of excess put demand. That's less alarming than the readings flagged in the previous note, when the PCR briefly pushed above two standard deviations. The 52-week range runs from 0.22 to 0.98, so the current level is elevated relative to recent history but far from panicked. The combination — shorts gradually building, puts running above average, analysts trimming targets — paints a picture of cautious rather than aggressive pre-event hedging.
On the ownership side, T. Rowe Price holds 24% of shares and added over 8.2 million shares in the most recent reporting period — a substantial commitment that frames how concentrated the institutional register is. BlackRock added 1.55 million shares to bring its stake to 3.4%. Insider activity has been consistently supportive: director Jean-Jacques Bienaime added shares again in mid-August at prices around $246, continuing a pattern of small open-market purchases that stretches back through May. CFO Scott Thomas Smith also bought in June. The net insider position over 90 days is a modest positive — around $777,000 net bought — with the one notable sell (an EVP disposing of 19,460 shares in May) the only meaningful offset.
The September 4 print is the event that resolves all of this. The last earnings release in August produced a 1-day decline of 2.7% and a five-day loss of just 0.25%, suggesting the stock absorbed the result relatively well at the index level. The note to watch is whether the Street's target-trimming ahead of this report reflects a genuine reset of near-term expectations — or simply housekeeping before a clean beat that has, by the company's own track record, been the more common outcome.
See the live data behind this article on ORTEX.
Open ASND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.